PeAF-BOX: Feasibility, Safety and Efficacy of PVI + Box Ablation in Persistent Atrial Fibrillation

Atrial Fibrillation Clinical Trial

— PeAF-BOX  

Official title:

PeAF-Box. A Study to Investigate the Feasibility, Safety and Efficacy of Isolating the Left Atrial Posterior Wall Adjunctive to Pulmonary Vein Isolation as First-line Therapeutical Strategy in Treatment of Persistent Atrial Fibrillation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05045131
• Other study ID #: PeAF-BOX study
• Status: Completed
• Phase: N/A
• Start date: March 17, 2016
• Est. completion date: November 14, 2020

Study information

• Verified date: September 2021
• Source: University Hospital, Gentofte, Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Title: PeAF-Box. Feasibility, Safety and Efficacy of Isolating the Left Atrial Posterior Wall (PWI) added to Pulmonary Vein Isolation (PVI) as First-Line Strategy in Treatment of Persistent Atrial Fibrillation (PeAF)

Design: A prospective, observational, single center, unblinded, clinical study with 3 years of follow-up and two interventional procedures: An index ablation procedure and a reassessment/ reablation procedure after 6 months.

Background: In patients with PeAF the effect of first-line ablation with pulmonary vein isolation (PVI) is smaller than in patients with paroxysmal atrial fibrillation (PAF), where PVI alone is effective in reducing symptoms and increasing quality of life. Adding PWI to PVI is increasingly used despite concerns about safety and efficacy.

Objectives: (1) To use PVI + PWI as first-line ablation-strategy in participants with PeAF and to assess the feasibility of obtaining that goal. (2) To assess the safety of applying this lesion set - in terms of heat-induced injury to the esophagus - using esophagoscopy. 3) To asses arrhythmia burden using continuous monitoring for 3 years after ablation. (4) To assess the durability of the PVI + PWI lesion set by a relook/ reablation procedure after 6 months. (5) To follow the effect of PVI + PWI on participants' quality of life over three years.

Study site: Dept of Cardiology - Electrophysiology Laboratory, Gentofte Hospital, University of Copenhagen.

Study population: 24 patients referred for ablation of PeAF are asked for informed consent for these elements that surpass standard treatment in PeAF: (1) Taking amiodarone for 3 weeks prior to the index procedure to 3 weeks after the procedure, (2) Additional ablation with PWI compared to standard first-line therapy with PVI only. (3) Implantation of an implantable cardiac monitor (ICM), (4) Post-procedure esophagoscopy, (5) Regular clinic visits for 3 years post procedure, (6) Undergoing an interventional relook/ reablation procedure 6 months after the index procedure.

Anticoagulation drugs during the procedure and follow up: To prevent thromboses participants are prescribed periprocedural oral anticoagulant treatment to be continued for shorter or longer/lifelong periods according to the participants' risk of thrombosis (the CHA2DS2-VASC score).

Anti-arrhythmic drugs (AADs): Except from periprocedural amiodarone treatment, no AADs are allowed during the follow-up apart from occurrence of otherwise untreatable arrhythmias.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: November 14, 2020
• Est. primary completion date: November 15, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients with symptomatic persistent atrial fibrillation (EHRA symptom class II or above)

• Prior failed treatment with at last one antiarrhythmic drug (Class I-IV)

• Clinical indication for ablation

• Persistent atrial fibrillation meeting both the following requirements:

• One or more episodes of atrial fibrillation lasting longer than seven days, regardless of mode of termination

• Estimated cumulated time in PeAF more than 3 months and less than 36 months

Exclusion Criteria:

• Contraindication for ablation

• Predominantly PAF phenotype

• Valvular Heart disease

• Previous ablation in heart

• Previous heart surgery (including valve surgery and coronary artery bypass grafting - CABG)

• Documented atrial flutter or other arrhythmia requiring ablation besides PVI

• Greatly enlarged left atrium on Trans thoracic Echocardiography (TTE ; diameter > 52 mm in males and diameter > 47 mm in females)

• LVEF < 35%

• Implanted pacemaker or defibrillator

• Presence of intramural thombus, tumor or other abnormality precluding catheter introduction

• Pregnancy

• Intolerance to Amiodarone

• Unstable angina pectoris

• Myocardial infarction within 3 months of inclusion

• History of blood clotting or bleeding anomalies

• Malignant disease (non metastatic skin cancer excluded)

• Severe obesity (Mody mass index > 35 kg/m^2)

• Active systemic infection

• Renal insufficiency (serum creatinine > 150 mmoles/liter)

• Psychiatric illness

• Substance abuse

• Participation in other clinical trials

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Procedure:
• Left atrial combined pulmonary vein isolation and posterior wall isolation

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
René Husted Worck	Biosense Webster, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Time to PVI	Time from index procedure start until all (or all isolatable) pulmonary veins are electrically isolated at index procedure. Metric: Min.	Data available immediately after index procedure
Other	Time to PVI + PWI	Time from index procedure start until all (or all isolatable) pulmonary veins and posterior walls are electrically isolated at index procedure. Metric: Min.	Data available immediately after index procedure
Other	Total procedure time	Time from index procedure start until all catheters are removed from the veins. Metric: Min.	Data available immediately after index procedure
Other	Ablation time PVI	Cumulated time of radiofrequency (RF) energy delivery required to achieve PVI during index procedure. Metric: min.	Data available immediately after index procedure
Other	Ablation time PVI + PWI	Cumulated time of RF delivery required to achieve PVI + PWI during index procedure. Metric: min.	Data available immediately after index procedure
Other	Fluoroscopy time PVI	Cumulated X-ray delivery time from start procedure until PVI achieved during index procedure. Metric: min.	Data available immediately after index procedure
Other	Fluoroscopy time PVI + PWI	Cumulated X-ray delivery time from start procedure until all catheters removed from the veins in index procedure. Metric: min.	Data available immediately after index procedure
Other	Fluoroscopy dose PVI	Cumulated X-ray dose to the participant from start procedure until PVI achieved during index procedure. Metric: Gy x cm^2	Data available immediately after index procedure
Other	Fluoroscopy dose PVI + PWI	Cumulated X-ray dose to the participant from start procedure until all catheters removed from the veins in index procedure. Metric: Gy x cm^2	Data available immediately after index procedure
Other	Index procedure vascular access complications	The number of participants developing a complication related to vascular access in the right groin. Metric: n/N in %	Data available one month after completion of the index procedure
Other	Index procedure tamponade/ effusions	The number of participants developing symptoms and signs of pericardial effusion during or after the procedure. Metric: n/N in %	Data available one day after completion of the index procedure
Other	Left atrial volume	The left atrial volume before the index procedure and before the reassessment procedure after 6 months. Estimated with 1) Contrast-CT scan of left atrium, 2) Echo - measured left atrial volume and 3) Left atrial volume estimated by electroanatomical mapping (Carto ®, Biosense Webster.Inc). Metric: ml.	Data available after completion of the reassessment procedure
Other	Left Ventricular Ejection Fraction (LVEF)	The left ventricular systolic function estimated by LVEF before the index procedure, before the reassessment procedure after 6 months and at 1 year follow-up. Metric: %	Data available 1 year after the index procedure
Primary	The safety of single procedure PVI + PWI	Defined as the incidence of inflammation or other injury to the esophagus detected under mandated esophagoscopy on the day after PVI + PWI with radiofrequency ablation. The endoscopy is carried out, assessed and electronically stored by a board-certified gastroenterologist. Metric: n/N in %.	Esophagoscopy is carried out at least 20 hours and less than 48 hours after the index ablation procedure
Secondary	Feasibility of a first-procedure PVI + PWI strategy	Defined as the ability to achieve complete bidirectional isolation of the left atrial posterior wall as well as all pulmonary veins at a reasonable cost in terms of procedure-, ablation and fluoroscopy times and total patient radiation exposure. Electrical isolation is assessed by visual inspection of electrocardiograms and classical electrophysiological pacing- and sensing maneuvers in the left atrium.	The data are available immediately after the end of the index PVI + PWI procedure
Secondary	Temperature in the esophagus during radiofrequency ablation	Defined as the maximum temperature measured in degrees Celsius with one decimal and evaluated for each individual ablation during point-by-point ablations to achieve PVI + PWI. Metric: Degrees Celsius.	The data are available immediately after the end of the index PVI + PWI procedure
Secondary	Durability of the PVI + PWI lesion set	Defined as the proportions of pulmonary veins and left atrial posterior walls remaining durably isolated when controlled at the six months reassessment procedure. Electrical isolation is assessed by visual inspection of electrocardiograms and classical electrophysiological pacing- and sensing maneuvers in the left atrium. Metric: n/N in %.	The data are available immediately after the end of the six months reassessment procedure
Secondary	AF recurrence short term	Defined as the proportion of participants with recurring atrial fibrillation of at least 2 minutes duration and the time to the first recurrence detected during continuous rhythm monitoring by the implanted loop recorder in the time frame of 90 days from end blanking period to 180 days post index procedure (time of scheduled reassessment procedure). Metric: n/N in %.	The data are available 180 days after the index procedure
Secondary	AF burden short term	Defined as cumulated time in atrial fibrillation (minutes) divided by the total number of minutes in the 90 days observation period between end blanking period and time of scheduled reassessment procedure. Metric: min/min in %.	The data are available 180 days after the index procedure
Secondary	AF recurrence long term	Defined as the proportion of participants with recurring atrial fibrillation of at least 2 minutes duration and the time to the first recurrence detected during continuous rhythm monitoring by the implanted loop recorder in the time frame between the reassessment / reablation procedure at 180 days and full three years (1080 days) observation time after the index procedure. Metric n/N in %.	The data are available 1080 days after the index procedure
Secondary	AF burden long term	Defined as cumulated time in atrial fibrillation (minutes) divided by the total number of minutes in the 900 days observation period between the 6 months reassessment/ reablation procedure and full three years observation time (1080 days). Moreover, AF burden is calculated every 3 to 6 months during the entire follow - up period. Metric: min./min. in %	The data are available 1080 days after the index procedure
Secondary	Long term efficacy PVI + PWI	Defined as incidence of anti arrhythmic drug therapy and repeat ablations between the the reassessment procedure at 180 days and end follow-up at 1080 days. Metric: number of patients and specification of drug	The data are available 1080 days after the index procedure
Secondary	Effect on quality of life by PVI + PWI	Defined as self reported scores obtained by repeat answering of the Atrial Fibrillation Effect on Quality of Life (AFEQT) score system. The questionnaire is administered every three to six months to coincide with clinic visits and calculation of AF burden. Metric: range [0-100]	Data are available from recruitment to end of follow-up at 3 years